The Role of Immunoprophylaxis in the Reduction of Disease Attributable to Respiratory Syncytial Virus

被引：16

作者：

Meissner, H. Cody ^{[1
]}

Bocchini, Joseph A., Jr. ^{[2
]}

Brady, Michael T. ^{[3
]}

Hall, Caroline B. ^{[4
,5
]}

Kimberlin, David W. ^{[6
]}

Pickering, Larry K. ^{[7
]}

机构：

[1] Tufts Med Ctr, Div Pediat Infect Dis, Boston, MA 02111 USA

[2] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Pediat, Shreveport, LA 71105 USA

[3] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA

[4] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA

[5] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA

[6] Univ Alabama Birmingham, Div Pediat Infect Dis, Birmingham, AL USA

[7] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA

来源：

PEDIATRICS | 2009年 / 124卷 / 06期

关键词：

PREMATURE-INFANTS BORN; INFECTION REQUIRING HOSPITALIZATION; INVESTIGATORS COLLABORATIVE NETWORK; HIGH-RISK INFANTS; GESTATIONAL-AGE; PALIVIZUMAB; CHILDREN; CANADA;

D O I：

10.1542/peds.2009-2346

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

引用

页码：1676 / 1679

页数：4

共 27 条

[1] Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children [J].

Abarca, Katia ;

Jung, Elizabeth ;

Fernandez, Pilar ;

Zhao, Liang ;

Harris, Brian ;

Connor, Edward M. ;

Losonsky, Genevieve A. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (04) :267-272

[2]

Anonymous, 2008, Morbidity and Mortality Weekly Report, V57, P462

[3]

Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]

[4] Risk factors for severe respiratory syncytial virus infection among Alaska Native children [J].

Bulkow, LR ;

Singleton, RJ ;

Karron, RA ;

Harrison, LH .

PEDIATRICS, 2002, 109 (02) :210-216

[5] Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons [J].

Carbonell-Estrany, X ;

Quero, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (09) :874-879

[6]

*CDCP, ACIP PROV REC PREV H

[7]

Connor E, 1997, PEDIATRICS, V99, P93

[8] Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease [J].

ElHassan, Nahed O. ;

Sorbero, Melony E. S. ;

Hall, Caroline B. ;

Stevens, Timothy P. ;

Dick, Andrew W. .

ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2006, 160 (10) :1070-1076

[9] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].

Feltes, TF ;

Cabalka, AK ;

Meissner, C ;

Piazza, FM ;

Carlin, DA ;

Top, FH ;

Connor, EM ;

Sondheimer, HM .

JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540

[10] Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain [J].

Figueras-Aloy, J ;

Carbonell-Estrany, X ;

Quero, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (09) :815-820

← 1 2 3 →